Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-46320
Titel: Overcoming limitations in exhaled breath aerosol analysis - Untargeted breathomics for the identification of endogenous breath biomarkers using LC-HRMS/MS
VerfasserIn: Maalouli Schaar, Juel
Hemmer, Selina
Manier, Sascha K.
Wagmann, Lea
Meyer, Markus R.
Sprache: Englisch
Titel: Analytica Chimica Acta
Bandnummer: 1365
Verlag/Plattform: Elsevier
Erscheinungsjahr: 2025
Freie Schlagwörter: Exhaled breath
Untargeted breathomics
Endogenous biomarker
LC-HRMS/MS
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Background Human exhaled breath (EB) aerosol is a suitable matrix for the non-invasive bioanalysis of both volatile but also non-volatile compounds. One of the key challenges in drug monitoring studies is the lack of standardization in EB sample collection. The aim of the present study was to use untargeted breathomics for identification of potential endogenous biomarkers in EB that could address these challenges. Results The Breath Explor impaction device was used to collect microparticles in EB aerosol from six healthy volunteers and six different sampling time points over a 1-h period (total number of samples = 36). Sample preparation consisted of an extraction with methanol and analysis was performed using reversed-phase and hydrophilic interaction-phase liquid chromatography coupled to high-resolution mass spectrometry. Results revealed the presence of a feature that could be reliably detected across all samples, thus representing a potential biomarker for standardizing EB aerosol sample collection. Although an annotation of this feature was not possible, it showed robustness and reproducibility in EB samples from healthy volunteers and could also be successfully detected in patient samples. Significance and novelty This study represents a step forward in overcoming the current limitation of EB analysis, the lack of standardization in sampling procedure. Nevertheless, further investigation including correlation studies and more diverse populations will be essential for the confirmation of the clinical relevance and application of this biomarker.
DOI der Erstveröffentlichung: 10.1016/j.aca.2025.344241
URL der Erstveröffentlichung: https://doi.org/10.1016/j.aca.2025.344241
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-463204
hdl:20.500.11880/40596
http://dx.doi.org/10.22028/D291-46320
ISSN: 0003-2670
Datum des Eintrags: 24-Sep-2025
Bezeichnung des in Beziehung stehenden Objekts: Supplementary data
In Beziehung stehendes Objekt: https://ars.els-cdn.com/content/image/1-s2.0-S000326702500635X-mmc1.xlsx
https://ars.els-cdn.com/content/image/1-s2.0-S000326702500635X-mmc2.pdf
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Experimentelle und Klinische Pharmakologie und Toxikologie
Professur: M - Prof. Dr. Markus Meyer
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
1-s2.0-S000326702500635X-main.pdf1,28 MBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons